ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 546

The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti-TNF in Spondyloarthritis Patients

Chamaida Plasencia1, Dora Pascual-Salcedo2, Sara Garcia-Carazo3, Gema Bonilla4, Leticia Lojo5, Laura Nuño6, Alejandro Villalba7, Diana Peiteado7, Concepcion Castillo-Gallego7, Florencia Arribas2, Daniel Nagore8, E. Martin-Mola9 and Alejandro Balsa4, 1Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain, 2Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, 3La PAZ University Hospital, RHEUMATOLOGY UNIT, Spain, Spain, 4Rheumatology, Hospital La Paz, Madrid, Spain, 5Rheumatology, Hospital Universitario La Paz, Spain, Spain, 6Hospital La Paz-IdiPaz, Madrid, Spain, 7Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 8Proteomika S.L., 9Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Activity score, anti-TNF therapy, antibodies and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Spondyloarthropathies (SpAs) encompass a heterogeneous group of diseases that primarily affect the axial skeleton and entheses. Although anti-TNF drugs have proven to be effective against SpA, approximately 30% of patients fail to respond or experience adverse events leading to treatment discontinuation. In rheumatoid arthritis, it has been shown that the development of antibodies (Abs) against the first anti-TNF treatment determines the response to the second anti-TNF treatment. Our aim was to assess whether the response to a second anti-TNF treatment after failing to respond to a first TNF antagonist is related to the previous development of Abs to the first TNF inhibitor.

Methods: We studied 33 patients diagnosed with SpA who began treatment with a second anti-TNF after failing to respond to the first anti-TNF: 23 (69.7%) patients with ankylosing spondylitis (AS), 6 (18.3%) with undifferentiated SpA, 3 (9%) with psoriatic SpA and 1 (3%) with SpA secondary to reactive arthritis. Clinical activity was assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS) at baseline (at the beginning of the 1º and 2º anti-TNF treatments) and at 6 months after switching. Clinical improvement was evaluated using the delta-ASDAS. The drug and anti-drug Ab (ADA) levels were measured by ELISA before each administration.

Results: Of the 33 patients examined, 18 (54.5%) were male. The mean age was 50.1±10.2 years, and 75% (21/28) were positive for HLA B27. All patients were initially treated with anti-TNF drugs; 14/33 (42.4%) were treated with infliximab (Ifx), 3/33 (9.1%) with adalimumab (Ada) and 16/33 (48.5%) with etanercept (Eta). Nine of 33 (27.3%) developed ADAs during the first biologic treatment [8 Abs to Ifx (ATI) and 1 Abs to Ada (ATA)]. Mainly due to inefficacy, the first anti-TNF was exchanged for a second anti-TNF: 7 (21.2%) switched to Ifx, 16 (48.5%) to Ada, 5 (15.2%) to Eta and 5 (15.1%) to golimumab (Gol). No differences in ASDAS were not observed at baseline in patients with or without ADAs to the first (3.35±0.87 with ADAs vs 3.51±1.04 without ADAs, p=0.953) and second (2.99±0.96 with ADAs vs 3.31±0.97 without ADAs, p=0.392) anti-TNF treatments.At six months after switching, patients who had previously developed ADAs had lower disease activity (1.76±0.98 with ADAs vs 2.79±1.11 without ADAs, p=0.020), and a trend was observed towards greater clinical improvement (delta-ASDAS 1.23±1.22 with ADAs vs 0.52±1.08 without ADAs, p=0.065). At six months after switching, most patients without ADAs were classified as having high or very high disease activity state by the ASDAS (18 out of 24 (75%) without ADAs vs 3 out of 9 (33.3%) with ADAs, p=0.022), and more patients with ADAs had inactive disease (2 out of 9 (22.2%) with ADAs vs 1 out of 24 (4.2%) without ADAs, p=0.022).

Conclusion: In SpA, the failure to respond to the first anti-TNF treatment due to the development of ADAs predicts a better clinical response to a second anti-TNF treatment. The study of immunogenicity in biological treatment failure may help predict the response to a second biological treatment for SpA.


Disclosure:

C. Plasencia,

Pfizer Inc,

2;

D. Pascual-Salcedo,

Pfizer Inc,

2;

S. Garcia-Carazo,
None;

G. Bonilla,
None;

L. Lojo,
None;

L. Nuño,
None;

A. Villalba,
None;

D. Peiteado,
None;

C. Castillo-Gallego,
None;

F. Arribas,
None;

D. Nagore,
None;

E. Martin-Mola,

Pfizer Inc,

2;

A. Balsa,

Pfizer Inc,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-immunogenicity-to-the-first-anti-tnf-therapy-determines-the-outcome-of-switching-to-a-second-anti-tnf-in-spondyloarthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology